title: AI-700 (Acusphere).
abstract: Acusphere is developing AI-700, perflubutane-filled synthetic polymer microspheres, for potential use as an ultrasound contrast agent for the assessment of myocardial perfusion. By April 2005, phase III enrollment was expected to be complete by early 2006, and the company expected to file an NDA in the first half of 2006.
authors.affiliation: Cardiology Department, University Hospital, Heraklion, Crete 71001, Greece. cardio@med.uoc.gr
authors.forename: Michael I
authors.initials: MI
authors.lastname: Hamilos
authors.forename: Alexandros P
authors.initials: AP
authors.lastname: Patrianakos
mesh_terms: D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism; D004452:Echocardiography; D005466:Fluorocarbons / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism; D006801:Humans; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging*; D013329:Structure-Activity Relationship
chemical_list: D003287:Contrast Media; D005466:Fluorocarbons; C108042:perfluorobutane